Biotech Target N V - Nov 14, 2024 Form 4 Insider Report for Molecular Templates, Inc. (MTEM)

Role: 10%+ Owner
Signature: By: /s/Ivo Betschart
Stock symbol: MTEM
Transactions as of: Nov 14, 2024
Transactions value $: -$433,334
Form type: 4
Date filed: 11/18/2024, 09:12 PM
Previous filing: Apr 4, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MTEM	Common Stock	Sale	-$846K	-1.28M	-100%	$0.66	0	Nov 14, 2024	Direct

Showing 1 to 1 of 1 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MTEM	Prefunded Warrants (right to buy)	Purchase	$316K	+135K		$2.35	135K	Apr 2, 2024	Common Stock	135K	$0.00	Direct	F1
transaction	MTEM	Common Warrants (right to buy)	Purchase	$96.2K	+769K		$0.13	769K	Apr 2, 2024	Common Stock	769K	$2.35	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Biotech Target N V is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.

Content

The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.

Remarks:

Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Molecular Templates, Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V.